Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct.
BACKGROUND
The authors retrospectively examined the predictive value of p53, MIB-1, and the argyrophilic nucleolar organizer regions (AgNOR) and examined the relationships among them in carcinoma of the extrahepatic bile duct (EHBD).


METHODS
Formalin fixed, paraffin embedded specimens from 54 patients with EHBD carcinoma were immunostained with MIB-1 against the Ki-67 nuclear antigen and p53 by the avidin-biotin peroxidase complex method, using the antigen retrieval technique of heating tissue sections in a microwave oven. The AgNOR proteins were localized at the optical level, as shown by a one-step silver staining technique.


RESULTS
MIB-1 and AgNOR were closely associated with lymph node metastasis (P < 0.01). The cumulative survival rate for patients with a low MIB-1 labeling index (LI) (< 29%) was significantly better than that for patients with a high MIB-1 LI (> or = 29%) in cases of EHBD carcinoma (P < 0.05), but MIB-1 was not an independent prognostic factor in multivariate analysis. The results indicated that AgNOR and p53 overexpression had no prognostic value. The authors detected p53 in 24 of the 54 EHBD carcinomas (44.4%). There was a significant correlation between MIB-1 and AgNOR (P < 0.01). The authors found that neither MIB-1 nor AgNOR correlated with p53 overexpression.


CONCLUSIONS
MIB-1 and AgNOR proved to be useful predictors of lymph node metastasis. The results of this study indicated that MIB-1 and AgNOR might be markers of the progression of EHBD carcinoma.
Suto
T
T
Department of Surgery I, School of Medicine, Iwate Medical University, Morioka, Japan.
Sugai
T
T
Nakamura
S
S
Funato
O
O
Nitta
H
H
Sasaki
R
R
Kanno
S
S
Saito
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D001650:Bile Duct Neoplasms / Q000235:genetics / Q000473:pathology*; D017734:Bile Ducts, Extrahepatic / Q000378:metabolism / Q000473:pathology*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D002277:Carcinoma / Q000235:genetics / Q000473:pathology* / Q000556:secondary; D004396:Coloring Agents; D005260:Female; D005404:Fixatives; D005544:Forecasting; D005557:Formaldehyde; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000032:analysis / Q000235:genetics*; D008207:Lymphatic Metastasis / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009697:Nucleolus Organizer Region / Q000235:genetics* / Q000648:ultrastructure; D016612:Paraffin Embedding; D011379:Prognosis; D012189:Retrospective Studies; D012834:Silver; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics*
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D004396:Coloring Agents; D005404:Fixatives; D019394:Ki-67 Antigen; D016159:Tumor Suppressor Protein p53; D005557:Formaldehyde; D012834:Silver